272 related articles for article (PubMed ID: 35718973)
1. Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.
Li N; Zhou H
Curr Pharm Des; 2022; 28(26):2131-2139. PubMed ID: 35718973
[TBL] [Abstract][Full Text] [Related]
2. Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.
Packer M
J Am Soc Nephrol; 2020 May; 31(5):907-919. PubMed ID: 32276962
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics.
Packer M
Am J Kidney Dis; 2021 Feb; 77(2):280-286. PubMed ID: 32711072
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control.
Takata T; Isomoto H
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922132
[TBL] [Abstract][Full Text] [Related]
5. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
Kawanami D; Matoba K; Takeda Y; Nagai Y; Akamine T; Yokota T; Sango K; Utsunomiya K
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524098
[TBL] [Abstract][Full Text] [Related]
7. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
8. Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
Curr Med Chem; 2023; 30(25):2850-2863. PubMed ID: 36045524
[TBL] [Abstract][Full Text] [Related]
9. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Weir MR
Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.
Kim NH; Kim NH
Diabetes Metab J; 2022 Jul; 46(4):543-551. PubMed ID: 35929172
[TBL] [Abstract][Full Text] [Related]
11. Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System.
Poursharif S; Hamza S; Braam B
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232506
[TBL] [Abstract][Full Text] [Related]
12. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
Wang YJ; Hao CM
Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277
[TBL] [Abstract][Full Text] [Related]
13. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
Packer M
Diabetes Obes Metab; 2020 May; 22(5):734-742. PubMed ID: 31916329
[TBL] [Abstract][Full Text] [Related]
14. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
15. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
Takakura S; Takasu T
Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
[TBL] [Abstract][Full Text] [Related]
16. Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease.
Speedtsberg ES; Tepel M
Front Endocrinol (Lausanne); 2023; 14():1281107. PubMed ID: 38174341
[TBL] [Abstract][Full Text] [Related]
17. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ; Day C; Bellary S
Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
[TBL] [Abstract][Full Text] [Related]
18. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
Elkazzaz SK; Khodeer DM; El Fayoumi HM; Moustafa YM
Life Sci; 2021 Sep; 280():119018. PubMed ID: 33549594
[TBL] [Abstract][Full Text] [Related]
19. Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Packer M
Am J Nephrol; 2020; 51(4):289-293. PubMed ID: 32126558
[TBL] [Abstract][Full Text] [Related]
20. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
